Given the critical roles of TAK1, NF-κB, and EGFR signaling in promoting tumor cell survival and therapy resistance, a deeper understanding of how DHC modulates these pathways could reveal novel strategies for cervical cancer treatment. The gene discussed is NFKB1; the disease is cervical carcinoma.